Aposense Ltd. (Formerly known as NST NeuroSurvival Technologies Ltd.) Cancer Drug Demonstrates 100% Oral Bioavailability in New Study
9/6/2011 9:17:27 AM
More...
|
Roche (RHHBY) to Use Aposense Ltd. (Formerly known as NST NeuroSurvival Technologies Ltd.) EarliTest(TM) for Imaging of Apoptosis in Oncology Clinical Trials
11/9/2010 9:55:36 AM
More...
|
Aposense Ltd. (Formerly known as NST NeuroSurvival Technologies Ltd.) Announces Successful Completion of IPO
6/7/2010 7:20:28 AM
More...
|
Ion Beam Applications (IBA) And Aposense Ltd. (Formerly known as NST NeuroSurvival Technologies Ltd.) Sign Strategic Collaboration to Commercialize Aposense(R) ML-10 for Molecular Imaging of Apoptosis
9/21/2009 11:10:21 AM
More...
|
Aposense Ltd. (Formerly known as NST NeuroSurvival Technologies Ltd.) Imaging Agent Detects Early Cell Death Induced by Radiation in Patients With Brain Metastases
6/16/2009 11:58:04 AM
More...
|
Aposense Ltd. (Formerly known as NST NeuroSurvival Technologies Ltd.) ML-10 Technology for Molecular Imaging of Apoptosis to Be Used by GlaxoSmithKline (GSK) in Experimental Oncology Studies
6/8/2009 11:59:03 AM
More...
|
Aposense Ltd. (Formerly known as NST NeuroSurvival Technologies Ltd.) Apoptosis Imaging Program for Cancer Therapy Monitoring Initiates a Phase II Multi-Center Study at Memorial Sloan-Kettering Cancer Center
12/15/2008 9:14:43 AM
More...
|
Aposense Ltd. (Formerly known as NST NeuroSurvival Technologies Ltd.) Completes $13.3 Million Financing
8/20/2008 6:15:12 AM
More...
|
NST NeuroSurvival Technologies Ltd. Release: APOSENSE(R) [18F]-ML-10 for Molecular Imaging of Apoptosis to Proceed to Phase I/II Trials
7/23/2008 10:44:28 AM
More...
|
Sigma-Aldrich Corporation (SIAL) Licenses From NeuroSurvival Technologies
2/26/2008 11:35:05 AM
More...
|